Analyst consensus rating
Genmab Analyst Rating: Strong Buy
Direct answer
Genmab's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $65.11.
Forecast evidence checked November 10, 2026.
Get free Genmab email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $54.07
- Average price target
- $65.11
- High price target
- $80.00
- Low price target
- $48.00
- Low target gap
- -11.2%
- Target upside
- +20.4%
- High target gap
- +48%
- Target range width
- 59.2%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- November 10, 2026
- Valid through
- November 17, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Genmab?
Genmab has a verified Strong Buy consensus. The same dataset has an average price target of $65.11.
How far are Genmab's low and high targets from the recorded price?
The low target implies -11.2%, while the high target implies +48%.
How many analysts are included in Genmab's consensus?
The verified consensus includes 10 analysts.
How is Genmab's target upside or downside calculated?
The average target of $65.11 is divided by the recorded price of $54.07, then one is subtracted to produce +20.4%. This does not guarantee a future return.
When was Genmab's analyst forecast verified?
The data was verified on 2026-11-10. The dataset is valid through 2026-11-17.